+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are observing how men with metastatic hormone-sensitive prostate cancer mHSPC respond to treatment with darolutamide combined with androgen deprivation therapy ADT, with or without the chemotherapy drug docetaxel. This international, open-label, multi-cohort study aims to understand the real-world effectiveness and safety of these treatments in routine medical practice. The study will enroll about 1,600 male patients primarily from Europe, focusing on those already decided to receive darolutamide before joining the study. Participants will be divided into two groups one receiving darolutamide plus ADT and docetaxel triplet therapy, and the other receiving darolutamide plus ADT without docetaxel doublet therapy. Treatment is given according to local standard care and chosen by the treating physician. No additional study-specific treatments or procedures are required, as data is collected during routine care visits over the study period. During the study, researchers will collect data on prostate-specific antigen PSA levels, survival rates, time to new treatments, progression of disease, adverse events, quality of life, and other clinical information. Data collection is done via electronic records during regular doctor visits with no extra tests beyond standard care. The study will last up to four years with periodic analyses to help improve understanding of darolutamide use in everyday clinical settings.

Age: 18Years +MALE
16 locations
S

Actively Recruiting

Researchers are investigating the mental workload impact of new lower limb prosthetic systems in people with above-knee amputations. This observational study aims to understand how different prosthetic technologies affect users, both in laboratory settings and daily life, by measuring mental workload and related functional outcomes. Participants use above-knee prostheses with prosthetic knees and feet and are assessed using various scales and tests over an 8-week period. The study collects data on goal achievement, walking tests, balance confidence, prosthesis satisfaction, and incidents of stumbles or falls to evaluate prosthetic system impact. Throughout the study, participants will undergo evaluations at the start, 4 weeks, and 8 weeks, including functional walking tests and questionnaires. A smartphone is required for participation to help design therapeutic goals and track progress. The study follows participants for 8 weeks, monitoring outcomes like the Goal Attainment Scale as the primary measure of success.

Age: 18Years - 84YearsAll Genders
1 location
R

Actively Recruiting

Researchers are evaluating the TASKA GEN2 multi-grip myoelectric hand prosthesis compared to other marketed multi-grip prostheses in adults with upper-limb amputation. This prospective multicentre randomized cross-over clinical follow-up study aims to assess specific function, upper-limb function, comfort, quality of life, satisfaction, and safety outcomes for people with transradial or transhumeral amputation or elbow disarticulation. The study is designed to better understand how the TASKA GEN2 prosthesis performs compared to the Michelangelo or I-Limb Ultra prostheses.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
S

Actively Recruiting

Venous leg ulcers are the final stage of chronic venous disease caused by advanced chronic venous insufficiency. These ulcers affect the quality of life of patients and are more common in older adults, with prevalence increasing with age. Managing chronic ulcers involves several care procedures, including debridement, which can be painful and only slightly relieved by pre-treatment analgesics. Music therapy, especially the standardized U-shaped method, has shown effectiveness in reducing pain and anxiety in various medical areas but has not yet been studied during debridement care for leg ulcers. This trial evaluates the use of musicotherapy alongside classic debridement care and usual analgesic treatment to reduce pain during leg ulcer care. Participants in the experimental group will receive a musicotherapy session using the Music Care application with headphones, starting 10 minutes before debridement, continuing during the procedure up to 40 minutes, and ending 10 minutes after. The control group will receive standard debridement and analgesic care without musicotherapy. Participants will be assessed for pain management effectiveness using the U-shaped musicotherapy method over an 18-month period. Researchers will measure pain levels, analgesic consumption, anxiety variations, blood pressure, and heart rate before and after debridement. The study is randomized, controlled, and open-label, aiming to provide data on musicotherapys role in pain and anxiety relief during chronic wound care.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying moderate to severe traumatic brain injury TBI complicated by subarachnoid hemorrhage SAH, focusing on the occurrence and evolution of cerebral vasospasm CV with clinical impact. CV is well described in aneurysmal SAH but less understood in traumatic cases, despite its potential impact on patient outcomes. This study aims to better define the incidence and characteristics of CV in this population at Martinique University Hospital using advanced imaging techniques. The study involves hospitalized patients with moderate or severe TBI Glasgow Score 13 and traumatic SAH seen on initial brain CT scan. Patients will receive routine clinical monitoring including daily transcranial Doppler TCD and biological assessments. If neurological deterioration or increased intracranial pressure occurs between days 3 and 12, a cerebral CT scan with an additional brain perfusion sequence will be performed to diagnose CV. Treatment to improve cerebral perfusion and manage intracranial pressure will continue as per standard care. Participants will be closely monitored during hospitalization with clinical exams, imaging, and neurological assessments. The study will estimate the incidence of CV with clinical impact over 42 months and describe its characteristics and risk factors. Neurological outcomes will be compared at 30 days and 6 months, with quality of life also assessed. Informed consent will be obtained from patients or their representatives, and data collection will include multiple follow-up points to understand CVs effect on recovery and prognosis.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are conducting an observational study to assess the performance and safety of OROSEDAL, an oral spray medical device, in children and adults with sore throat or minor oral lesions such as minor aphthous ulcers and oral lichen planus. This study takes place in real-life general practice settings and includes patients aged 8 years and older who have had symptoms for less than 15 days and significant pain levels. The goal is to gather real-world information on how OROSEDAL is used and its effects on pain and discomfort. Participants are those who have been prescribed OROSEDAL independently of the study. They will use the product as directed, and data will be collected at the start, daily through self-assessment diaries, and at Day 6 7 days or upon early study exit. The study focuses on pain relief, swallowing discomfort, treatment use, safety, device performance, and patient compliance in typical care settings. During the study, participants will record their pain, swallowing discomfort, symptoms, and any adverse events daily. Researchers will evaluate pain reduction at Day 1 evening as the primary outcome and assess additional measures such as pain at Day 6, immediate pain relief after use, and overall patient-rated effectiveness. Safety and any device issues will be monitored from inclusion through Day 6. The study duration per participant is approximately 6 days.

Age: 8Years +All Genders
1 location
O

Actively Recruiting

Researchers are evaluating the clinical performance and safety of RIVADOUCE VEGETABLE SKINCARE OIL in preventing pressure ulcers in adults at risk. This observational post-market clinical follow-up study is conducted in real-life settings across multiple centers, focusing on patients with a Braden Scale score under 18 and no existing pressure ulcers. The study follows international standards and aims to gather updated evidence for device certification under EU regulations. The skincare oil is applied gently by effleurage to pressure-prone areas such as the sacrum, heels, ischial, and trochanteric regions as part of routine prevention protocols. A total of 252 adult patients will be enrolled and followed for 35 days, with a small allowance of 5 days variation. The study does not involve randomization or control groups, focusing on real-life product use and monitoring. Participants will be monitored for the development of pressure ulcers, timing of their onset, progression, and any adverse events potentially related to the device. Compliance with product use will also be tracked. The primary outcome is the proportion of patients developing at least one pressure ulcer of stage 1 or higher during the study period. Safety and performance data collected will help support ongoing product approval and clinical use.

Age: 18Years +All Genders
1 location
O

Actively Recruiting

Transthyretin amyloid cardiomyopathy ATTR-CM is a progressive heart condition caused by the buildup of an abnormal protein called transthyretin in the heart, which can impair heart function and worsen symptoms over time. Acoramidis is a medicine approved for adults with wild-type or hereditary ATTR-CM. While its benefits have been shown in clinical trials, more information is needed about how it is used and how patients fare in everyday medical care. This observational study in France follows patients receiving acoramidis as part of their usual medical treatment. Participants take acoramidis orally at a dose of 712 mg twice daily. No experimental treatments or extra medical procedures are required beyond standard care. The study collects data directly from hospitals and from the Healthcare European Amyloidosis Registry to understand patient experiences and treatment use. Participants will be followed for 12 months after starting acoramidis. During this time, researchers will assess quality of life, daily functioning, and overall well-being at 3, 6, 9, and 12 months using patient-completed questionnaires. Additional information about patient characteristics, treatment patterns, safety, and tolerability will also be collected. This research aims to improve understanding and care of people living with ATTR-CM.

Age: 18Years +All Genders
1 location
R

Actively Recruiting

Researchers are studying treatments for participants with locally advanced or metastatic urothelial carcinoma lamUC who have progressed during or after prior therapy with enfortumab vedotin EV plus pembrolizumab. This global, multicenter, randomized, open-label Phase 23 trial aims to evaluate the combination of Datopotamab Deruxtecan Dato-DXd plus carboplatin or cisplatin compared to gemcitabine plus carboplatin or cisplatin. The initial Phase 2 part will assess preliminary efficacy and safety to determine the recommended Phase 3 dose RP3D, with the Phase 3 part starting based on these findings.

Age: 18Years +All GendersPhase 2Phase 3
100 locations

1-10 of 15

1